Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.
Aim(s): We report long-term SD in a glucagonoma pt enrolled in RADIANT-1.
Materials and methods: A man aged 46 was diagnosed with glucagonoma in 1990 with tumors in the pancreas (4 cm) and liver (5 cm): p-glucagon >1000 ng/L (ref,
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Jenny Falkerby
To read results and conclusion, please login ...
Further abstracts you may be interested in